Valuation: Black Diamond Therapeutics, Inc.

Market Cap 113M 98.86M 91.06M 84.52M 161M 10.77B 163M 1.09B 424M 5.29B 424M 415M 18.33B P/E 2026 *
-3.04x
P/E 2027 * -1.96x
Enterprise Value 113M 98.86M 91.06M 84.52M 161M 10.77B 163M 1.09B 424M 5.29B 424M 415M 18.33B EV / Sales 2026 *
20.3x
EV / Sales 2027 * -
Free-Float
99.35%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 62 2023-09-15
Chief Tech/Sci/R&D Officer 51 2021-08-10
Director of Finance/CFO 41 2024-10-06
Director TitleAgeSince
Director/Board Member 61 2017-02-28
Director/Board Member 47 2019-11-30
Director/Board Member 50 2018-11-30
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 115M
-2.14%+3.51%+74.05%+131.10% 59.1B
-0.93%-2.54%+73.64%+93.71% 55.19B
-3.71%-0.35%-14.61%-11.19% 24.67B
-0.05%+6.49%+14.05%+451.36% 24.19B
-1.59%+7.63%+48.66%-1.48% 19.69B
-2.19%+6.34%+40.74%-29.60% 17.56B
+3.58%+13.78%+196.41%+348.55% 16.22B
-0.67%+19.10%+47.42% - 14.84B
-0.57%+2.30%+20.33%+187.27% 14.04B
Average -0.82%+7.79%+55.63%+146.22% 27.28B
Weighted average by Cap. -1.22%+5.67%+58.12%+135.68%

Financials

2026 *2027 *
Net sales 5.56M 4.87M 4.48M 4.16M 7.9M 530M 8.01M 53.64M 20.88M 260M 20.86M 20.41M 902M -
Net income -40.47M -35.45M -32.65M -30.3M -57.55M -3.86B -58.33M -391M -152M -1.9B -152M -149M -6.57B -70.04M -61.35M -56.5M -52.45M -99.59M -6.68B -101M -676M -263M -3.28B -263M -257M -11.37B
Net Debt - -
Logo Black Diamond Therapeutics, Inc.
Black Diamond Therapeutics, Inc. is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The Company’s MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat central nervous system disease. The Company is advancing a Phase 2 NSCLC trial of BDTX-1535, a brain-penetrant fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting EGFR-mutant NSCLC and glioblastoma. Its BDTX-4933 pipeline product is out-licensed to Servier. BDTX-4933 is designed to target RAS and RAF alterations in solid tumors. It is exploring partnership opportunities for its FGFR2/3 selective development candidate BDTX-4876.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
1.970USD
Average target price
9.857USD
Spread / Average Target
+400.36%

Quarterly revenue - Rate of surprise